Literature DB >> 31832219

Clinical evaluation of fitness to drive in patients with brain metastases.

Cristina Valencia-Sanchez1, Vanessa C Gorelkin2, Maciej M Mrugala1, Akanksha Sharma1, Sujay A Vora3, Jonathan B Ashman3, Thomas B Daniels3, Michele Y Halyard3, William G Rule3, Nan Zhang4, Richard J Butterfield4, Steven E Schild3, Alyx B Porter1.   

Abstract

BACKGROUND: Guidelines to provide recommendations about driving restrictions for patients with brain metastases are lacking. We aim to determine whether clinical neurologic examination is sufficient to predict suitability to drive in these patients by comparison with an occupational therapy driving assessment (OTDA).
METHODS: We prospectively evaluated the concordance between neurology assessment of suitability to drive (pass/fail) and OTDA in 41 individuals with brain metastases. Neuro-oncology evaluation included an interview and neurological examination. Participants subsequently underwent OTDA during which a battery of objective measures of visual, cognitive, and motor skills related to driving was administered.
RESULTS: The mean age of patients who failed OTDA was age 68.9 years vs 59.3 years in the group members who passed (P = .0046). The sensitivity of the neurology assessment to predict driving fitness compared with OTDA was 16.1% and the specificity 90%. The 31 patients who failed OTDA were more likely to fail Vision Coach, Montreal Cognitive Assessment, and Trail Making B tests.
CONCLUSIONS: There was poor association between the assessment of suitability to drive by neurologists and the outcome of the OTDA in patients with brain metastases. Subtle deficits that may impair the ability to drive safely may not be evident on neurologic examination. The positive predictive value was high to predict OTDA failure. Age could be a factor affecting OTDA performance. The results raise questions about the choice of assessments in making recommendations about driving fitness in people with brain metastases. OTDA should be strongly considered in patients with brain metastases who wish to continue driving.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  brain metastases; fitness to drive

Year:  2019        PMID: 31832219      PMCID: PMC6899051          DOI: 10.1093/nop/npz027

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  10 in total

1.  Current practices of driving restriction implementation for patients with brain tumors.

Authors:  Sayana Thomas; Minesh P Mehta; John S Kuo; H Ian Robins; Deepak Khuntia
Journal:  J Neurooncol       Date:  2010-10-23       Impact factor: 4.130

2.  Utility of the MOCA as a cognitive predictor for fitness to drive.

Authors:  Patrick Esser; Stephen Dent; Clare Jones; Bryony Jane Sheridan; Andrew Bradley; Derick Treharne Wade; Helen Dawes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-05-18       Impact factor: 10.154

3.  Interactive Tools for Measuring Visual Scanning Performance and Reaction Time.

Authors:  Johnell Brooks; Julia Seeanner; Sarah Hennessy; Joseph Manganelli; Matthew Crisler; Patrick Rosopa; Casey Jenkins; Michael Anderson; Nathalie Drouin; Leah Belle; Constance Truesdail; Stephanie Tanner
Journal:  Am J Occup Ther       Date:  2017 Mar/Apr

4.  Drawing clocks and driving cars.

Authors:  Barbara Freund; Stefan Gravenstein; Rebecca Ferris; Bonnie L Burke; Elias Shaheen
Journal:  J Gen Intern Med       Date:  2005-03       Impact factor: 5.128

Review 5.  Brain metastases: treatment options to improve outcomes.

Authors:  Phillip Davey
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 6.  Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases.

Authors:  Susan G R McDuff; Zachary J Taich; Joshua D Lawson; Parag Sanghvi; Eric T Wong; Fred G Barker; Fred H Hochberg; Jay S Loeffler; Peter C Warnke; Kevin T Murphy; Arno J Mundt; Bob S Carter; Carrie R McDonald; Clark C Chen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-05-28       Impact factor: 10.154

7.  Cognition in patients with newly diagnosed brain metastasis: profiles and implications.

Authors:  Adam Gerstenecker; Louis B Nabors; Karen Meneses; John B Fiveash; Daniel C Marson; Gary Cutter; Roy C Martin; Christina A Meyers; Kristen L Triebel
Journal:  J Neurooncol       Date:  2014-07-18       Impact factor: 4.130

8.  The short test of mental status. Correlations with standardized psychometric testing.

Authors:  E Kokmen; G E Smith; R C Petersen; E Tangalos; R C Ivnik
Journal:  Arch Neurol       Date:  1991-07

9.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors:  Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

10.  Clinical Utility of the Trail-Making Test as a Predictor of Driving Performance in Older Adults.

Authors:  George D Papandonatos; Brian R Ott; Jennifer D Davis; Peggy P Barco; David B Carr
Journal:  J Am Geriatr Soc       Date:  2015-10-27       Impact factor: 5.562

  10 in total
  2 in total

1.  Patients with pretreatment leukoencephalopathy and older patients have more cognitive decline after whole brain radiotherapy.

Authors:  Matthew Chan; David Ferguson; Elaine Ni Mhurchu; Ren Yuan; Lovedeep Gondara; Michael McKenzie; Robert Olson; Brian Thiessen; Nafisha Lalani; Roy Ma; Alan Nichol
Journal:  Radiat Oncol       Date:  2020-11-25       Impact factor: 3.481

Review 2.  Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication.

Authors:  Sabine Seidel; Tim Wehner; Dorothea Miller; Jörg Wellmer; Uwe Schlegel; Wenke Grönheit
Journal:  Neurol Res Pract       Date:  2022-09-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.